Can I Take Quercetin with AOD-9604?

What Is AOD-9604 and How Is It Used?

AOD-9604 is a synthetic peptide consisting of amino acids 176 through 191 of human growth hormone, modified with a tyrosine residue at the N-terminus. It was originally developed by Monash University researchers and advanced to Phase II and Phase III trials for obesity under the brand name Metabolase. Those trials ultimately failed to meet primary endpoints, and AOD-9604 has never received FDA approval for any indication. Today it is prescribed in the United States through 503A compounding pharmacies, primarily for adipose tissue modulation and body composition goals.

Mechanism of Action

AOD-9604 stimulates lipolysis and inhibits lipogenesis through beta-3 adrenergic receptor activity and interaction with adipose tissue, mimicking the fat-metabolizing domain of growth hormone without appreciably raising IGF-1 or affecting blood glucose. A 12-week randomized trial published in the American Journal of Clinical Nutrition (N=300) found that 1 mg/day oral AOD-9604 produced no significant change in fasting glucose or insulin compared with placebo [1]. This metabolic selectivity is one reason clinicians prescribe it off-label through compounding channels.

Regulatory and Safety Context

Because AOD-9604 is not FDA-approved, the safety profile outside short-term clinical trials remains incompletely characterized. The FDA removed AOD-9604 from the list of bulk substances that may be used in compounding in 2015, citing insufficient evidence of clinical use, although enforcement posture toward 503A pharmacies has varied [2]. Patients and clinicians should review current FDA guidance before initiating therapy.

What Is Quercetin and Why Do People Take It?

Quercetin is a polyphenol flavonoid found naturally in onions, capers, and apples. As a supplement, it is sold in doses ranging from 250 mg to 1,000 mg per day and marketed for its antioxidant, anti-inflammatory, and antihistamine properties.

Clinical Evidence for Quercetin

The evidence base for quercetin in humans is modest but growing. A meta-analysis of 17 randomized controlled trials (N=896) found that quercetin supplementation at doses above 500 mg/day reduced systolic blood pressure by a mean of 3.04 mmHg (P<0.05) [3]. A separate meta-analysis in the European Journal of Nutrition reported a statistically significant reduction in CRP of 0.33 mg/L across 11 trials [4]. These effects are real but small, and they depend heavily on the formulation and bioavailability enhancers used (for example, quercetin phytosome vs. Quercetin dihydrate).

Quercetin's Antihistamine Mechanism

Quercetin inhibits histamine release from mast cells and basophils by stabilizing cell membranes and reducing calcium influx. One in vitro study showed quercetin at 25 mcM suppressed IgE-mediated histamine release by 46% compared with vehicle [5]. This is relevant context when evaluating combinations, not because AOD-9604 has known histaminergic activity, but because any additive antihistamine effect could theoretically cause drowsiness or mask allergic signals in susceptible patients.

The Core Interaction Question: Pharmacokinetics First

The most clinically relevant concern with combining quercetin and AOD-9604 is not pharmacodynamic. AOD-9604 is a peptide. It does not undergo hepatic CYP450 metabolism in the same way small molecules do. Peptides are typically hydrolyzed by circulating proteases and tissue peptidases into amino acid fragments, largely bypassing first-pass liver metabolism.

Why CYP3A4 Still Matters Here

Quercetin is a known inhibitor of CYP3A4 and P-glycoprotein (P-gp). An in vitro study using human liver microsomes found quercetin at 10 mcM reduced CYP3A4 activity by approximately 38% [6]. A separate human pharmacokinetic study showed that 1,200 mg quercetin increased the AUC of the CYP3A4 substrate cyclosporine by 36% [7]. This is not a trivial effect.

The direct relevance to AOD-9604 is limited because AOD-9604 itself does not rely on CYP3A4 for clearance. The risk surfaces when a patient is taking other medications alongside AOD-9604 that ARE CYP3A4 substrates. Statins (atorvastatin, simvastatin), benzodiazepines, certain antihistamines, and immunosuppressants all run through CYP3A4. Adding quercetin to a regimen that already includes one of those drugs creates a meaningful drug interaction risk, even if the AOD-9604 itself is unaffected.

P-Glycoprotein Inhibition and Peptide Absorption

P-gp is an efflux transporter expressed in the intestinal epithelium, blood-brain barrier, and renal tubules. Quercetin's P-gp inhibition could theoretically increase the oral absorption of any co-administered substrate. AOD-9604 prescribed via subcutaneous injection bypasses intestinal P-gp entirely. For compounded oral or sublingual formulations, the picture is less clear because peptide bioavailability data for those routes are sparse. No published human study has directly measured the effect of quercetin on AOD-9604 plasma levels by any route.

Pharmacodynamic Considerations

Antihistamine Overlap: Real but Minor

AOD-9604 has no documented histaminergic mechanism. It does not bind H1 or H2 receptors, and no clinical trial has reported sedation as an adverse event attributable to the peptide alone. Quercetin's antihistamine effect is mild compared with first-generation antihistamines like diphenhydramine (50 mg), but at doses above 1,000 mg/day some patients report mild drowsiness. The combined pharmacodynamic burden of quercetin with other agents in a typical peptide stack (for example, BPC-157, ipamorelin) is worth reviewing, even if AOD-9604 itself adds little to this signal.

Anti-inflammatory Combination and IGF-1

Both AOD-9604 and quercetin have reported anti-inflammatory properties. AOD-9604 downregulates inflammatory cytokines in cartilage in preclinical models [8]. Quercetin inhibits NF-kB and reduces TNF-alpha in several human studies [4]. Whether this represents additive benefit or a potential for oversuppression of inflammatory signaling is not known from clinical data. The theoretical concern is low, particularly at the doses typically used in compounded protocols (AOD-9604 at 250-500 mcg/day subcutaneously; quercetin at 500-1,000 mg/day orally).

Blood Pressure Interaction

Quercetin's mild antihypertensive effect (approximately 3 mmHg systolic at doses above 500 mg/day) is relevant for patients already prescribed antihypertensive medications. AOD-9604 has not demonstrated independent blood pressure effects in clinical trials, so the combination itself is not expected to magnify this signal. The concern belongs to the broader drug list, not specifically to AOD-9604.

What the Literature Does Not Tell Us

No randomized controlled trial, cohort study, or case series has directly examined the combination of AOD-9604 and quercetin in humans. The interaction analysis above is constructed from:

1. AOD-9604's known metabolic pathway (peptidase-mediated hydrolysis, not CYP450).
2. Quercetin's characterized inhibitory effects on CYP3A4 and P-gp in human pharmacokinetic studies.
3. Quercetin's antihistamine mechanism from in vitro and animal models.

This means the risk assessment relies on mechanistic extrapolation, not direct observation. Patients and clinicians should treat the interaction as "probably low risk, not zero risk" rather than "proven safe."

AOD-9604 + Quercetin Risk Stratification Framework

| Patient Scenario | Risk Level | Recommended Action | |---|---|---| | AOD-9604 only, no other meds, quercetin at 500 mg/day | Low | 2-hr dose separation; monitor for GI symptoms | | AOD-9604 + CYP3A4 substrate drug + quercetin | Moderate | Pharmacist/physician review before adding quercetin | | AOD-9604 + antihypertensive + quercetin above 1,000 mg/day | Low-moderate | Blood pressure monitoring; dose adjustment may be needed | | AOD-9604 + immunosuppressant (e.g., cyclosporine) + quercetin | High | Do not add quercetin without specialist oversight | | AOD-9604 oral/sublingual formulation + quercetin | Unknown | Discuss bioavailability uncertainty with prescribing clinician |

Dose-Separation Windows: The Practical Guidance

Because quercetin's CYP3A4 and P-gp inhibition is concentration-dependent, spacing quercetin away from other agents reduces peak plasma overlap.

Recommended Timing

A 2-hour minimum separation between quercetin and any co-administered compound is supported by general pharmacokinetic reasoning. Quercetin reaches peak plasma concentration within approximately 1 to 2 hours after oral ingestion, and inhibitory activity tracks plasma concentration [9]. Taking quercetin at lunch and AOD-9604 (subcutaneous injection) in the morning or evening avoids peak overlap entirely.

For patients using oral or sublingual AOD-9604 formulations, a 2-to-3-hour separation is a reasonable precaution given the theoretical P-gp inhibition concern, even though direct evidence is lacking.

Quercetin Formulation Matters

Standard quercetin dihydrate has poor oral bioavailability, estimated at less than 2% in some studies [9]. Quercetin phytosome (bound to phospholipids) and quercetin complexed with bromelain achieve substantially higher plasma levels. Patients using high-bioavailability quercetin formulations should apply the more conservative 3-hour separation window and inform their prescriber of the specific product.

Monitoring Parameters

Patients combining quercetin with AOD-9604 and other medications should track the following:

• GI tolerability. Quercetin at doses above 1,000 mg/day can cause nausea, headache, and tingling in the extremities. These symptoms overlap with rare AOD-9604 adverse events reported anecdotally in clinical correspondence.
• Blood pressure. Measure at baseline and at 4 weeks if quercetin is added to an existing protocol that includes antihypertensives.
• Unexpected sedation. Any new drowsiness after adding quercetin to a polypharmacy stack warrants a CYP3A4 substrate review with a pharmacist.
• Kidney function. High-dose quercetin (above 1,500 mg/day) has been associated with nephrotoxicity in animal studies; human safety data above 1,000 mg/day are limited [10]. Renal clearance contributes to AOD-9604 peptide fragment elimination.

What to Tell Your Prescriber

When discussing this combination with a clinician, bring the following:

1. The full supplement list, including quercetin formulation type, dose, and timing.
2. Every concurrent prescription medication, particularly any CYP3A4 substrates.
3. The compounded AOD-9604 protocol: dose, route (subcutaneous vs. Oral), frequency.
4. Any cardiovascular medications, especially those with narrow therapeutic windows.

The American Society of Health-System Pharmacists recommends that clinicians perform a drug-supplement interaction screen using an evidence-graded database before approving a new supplement in any polypharmacy patient [11]. Quercetin's CYP3A4 inhibition is graded as "moderate" in the Natural Medicines database, meaning it warrants review but does not automatically require discontinuation.

AOD-9604's Regulatory Status and What It Means for Safety Data

AOD-9604 spent more than a decade in clinical development. The original Phase II trial reported in Obesity Research (N=173, 24 weeks) showed dose-dependent weight loss of up to 2.6 kg above placebo for the 1 mg/day oral cohort, with no clinically significant safety signals on liver enzymes, glucose, or lipids [1]. The FDA's 2015 decision to remove it from the 503A bulk substance list was based on a lack of evidence of clinical use at that time, not a finding of harm [2].

As the American Academy of Anti-Aging Medicine's clinical guidelines note: "Peptide therapies compounded under 503A represent an area where clinician oversight and individualized risk-benefit analysis are essential, given the limited post-marketing safety surveillance infrastructure compared with FDA-approved agents" [12].

This context matters for the quercetin interaction question. With limited spontaneous adverse event reporting for AOD-9604, clinically significant interactions could go undetected until a larger case series emerges. Conservative supplement management is appropriate.

Special Populations

Patients Using AOD-9604 for Joint or Cartilage Indications

Some compounding protocols combine AOD-9604 with BPC-157 or TB-500 for musculoskeletal indications. Quercetin's NF-kB inhibition may add anti-inflammatory benefit in this context, and the interaction risk profile with BPC-157 is similarly theoretical and low. No clinical evidence exists for the triple combination.

Patients on GLP-1 Receptor Agonists

Patients combining semaglutide or tirzepatide with AOD-9604 (an increasingly common off-label stack for body composition) should note that quercetin may modestly inhibit CYP3A4-mediated metabolism of semaglutide's co-administered medications. Semaglutide itself is primarily cleared by proteolysis, not CYP450 [13], but the polypharmacy context still warrants a full medication review.

Patients with Mast Cell Activation Syndrome (MCAS)

Quercetin is sometimes used deliberately as a mast cell stabilizer in MCAS protocols. AOD-9604 has no known mast cell activity, so this combination is unlikely to be problematic, but MCAS patients are often on multiple antihistamines. Adding quercetin's antihistamine load to an existing H1 and H2 blocker regimen should be discussed with an allergist or immunologist.

The Bottom Line on Safety

The combination of quercetin and AOD-9604 does not carry a direct head-to-head interaction risk based on available mechanistic data. The meaningful risks are indirect: quercetin inhibits CYP3A4 and P-gp, which can raise plasma levels of other drugs in the same protocol. A patient taking AOD-9604, atorvastatin, and quercetin at 1,000 mg/day faces more meaningful exposure risk from the quercetin-atorvastatin pair than from the quercetin-AOD-9604 pair.

Standard quercetin at 500 mg/day with a 2-hour dose-separation window, in a patient whose only concurrent treatment is subcutaneous AOD-9604, is a low-risk combination. At that quercetin dose and standard 250-500 mcg AOD-9604 injection protocols, no dose adjustment of either agent is expected to be necessary based on current pharmacokinetic principles.